Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 14/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17668243 | 0.84 | KDR (1.00) | KDRPDGFRBAURKBFLT3KIT | |
| SCHEMBL17668181 | 0.83 | PDGFRB (1.00) | KDRPDGFRB | |
| SCHEMBL1103738 | 0.80 | PDGFRB (0.66) | KDRPDGFRBMAP4K4FYN | |
| SCHEMBL26917340 | 0.78 | PDGFRB (0.63) | KDRPDGFRBMAP4K4FYN | |
| SCHEMBL29858130 | 0.78 | PDGFRB (0.63) | KDRPDGFRBMAP4K4FYN | |
| SCHEMBL423204 | 0.77 | PDGFRB (0.61) | KDRPDGFRBCLK4 | |
| SCHEMBL3665719 | 0.77 | PDGFRB (0.62) | KDRPDGFRBAURKBFLT3CLK4 | |
| SCHEMBL22820659 | 0.76 | PDGFRB (0.60) | KDRPDGFRBFYNAXLMKNK2 | |
| SCHEMBL22820405 | 0.75 | PDGFRB (0.60) | KDRPDGFRBFYNMET | |
| SCHEMBL17668200 | 0.75 | PDGFRB (1.00) | KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669265-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2020-06-02 | — | — | US | claimed |
| US-20180111921-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2018-04-26 | — | — | US | claimed |
| US-20170107210-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-04-20 | — | — | US | claimed |
| US-20160102080-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-14 | — | — | US | claimed |
| US-20210115029-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115029-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10669265-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669265-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10633373-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633373-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180111921-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111921-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-9868726-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868726-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170107210-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107210-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-04-20 | — | — | US | disclosed |
| US-9371314-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371314-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160102080-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160102080-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102080-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | PDXK, MAP4K5, MAP4K2 | KDR 226/4885PDGFRB 127/4885AURKB 322/4885 |
| US-10633373-B2 | Pyridyl benzothiophenes as kinase inhibitors | PDXK, MAP4K5, MAP4K2 | KDR 226/4885PDGFRB 127/4885AURKB 322/4885 |
| US-20180111921-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | PDXK, MAP4K5, MAP4K2 | KDR 226/4885PDGFRB 127/4885AURKB 322/4885 |
| US-20170107210-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | PDXK, MAP4K5, MAP4K2 | KDR 226/4885PDGFRB 127/4885AURKB 322/4885 |
| US-20210115029-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | PDXK, MAP4K5, MAP4K2 | KDR 226/4885PDGFRB 127/4885AURKB 322/4885 |
| US-10669265-B2 | Pyridyl benzothiophenes as kinase inhibitors | PDXK, MAP4K5, MAP4K2 | KDR 226/4885PDGFRB 127/4885AURKB 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.